Trial Profile
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 28 Nov 2023 Planned End Date changed from 1 Oct 2026 to 31 Dec 2030.
- 28 Nov 2023 Planned primary completion date changed from 1 Oct 2025 to 31 Dec 2029.
- 01 Aug 2022 Results assessing predictors of 18F-DCFPyL PET/CT positivity in patients with biochemical recurrence of prostate cancer after local therapy using data from two clinical studies: NCT02825875 and NCT03181867 published in the Journal of Nuclear Medicine